Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope.
Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale.
Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need.
The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope.
Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale.
Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need.
The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
Location: United States
Employees: 51-200
Total raised: $594M
Founded date: 2019
Investors 4
| Date | Name | Website |
| 07.06.2024 | Koch Disru... | kochdisrup... |
| - | 8VC | 8vc.com |
| 27.10.2020 | Eclipse Ve... | eclipse.vc |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 29.01.2026 | Series D | $257M | EDBI |
| 23.08.2023 | Series C | $255M | - |
| 05.05.2021 | Series B | $82M | Eclipse Ve... |
Mentions in press and media 28
| Date | Title | Description |
| 30.01.2026 | Cellares Secures $257M to Industrialize Cell Therapy Manufacturing | Cellares, a leading Integrated Development and Manufacturing Organization (IDMO), just secured $257 million in Series D funding. This pivotal round, co-led by investment giants BlackRock and Eclipse, elevates Cellares' total capital to an i... |
| 29.01.2026 | Cellares: $257 Million Series D Closed To Scale Automated Cell Therapy Manufacturing | Cellares has raised $257 million in a Series D financing co-led by investment funds managed by BlackRock and Eclipse, bringing total capital raised to $612 million. The round brings in a slate of new investors, including accounts advised by... |
| 28.01.2026 | NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania' | NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Sch... |
| 28.01.2026 | Cellares Raises $257M in Series D Funding | Cellares, a San Francisco, CA-based Integrated Development and Manufacturing Organization (IDMO), raised $257M in Series D funding. The round was led by BlackRock and Eclipse. Other investors included T. Rowe Price Investment Management, In... |
| 28.01.2026 | Biology: Cellares Raises $257M to Industrialize Cell Therapy | What You Should Know The News: Cellares has raised $257M in Series D financing, bringing its total capital to $612 million. The round was co-led by BlackRock and Eclipse. The Tech: Cellares is building the world’s first IDMO (Integrated Dev... |
| 16.01.2026 | Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands | Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commerciee... |
| 13.06.2025 | Munich unicorn hothouse targets expansion, but discounts London | A famed Munich-based business course, which has spawned nine unicorns including Trade Republic and Monzo, is looking to offer its study programme in new European markets, but says that London is an unlikely destination. The Center for Digit... |
| 12.02.2025 | From alumni to investors: CDTM-backed fund raises €8.2 million for early-stage startups | Munich-based CDTM Venture Fund, part of the Center for Digital Technology & Management (CDTM), has today announced a €8.2 million raise to support CDTM-affiliated startups, driven by contributions from 316 alumni. The investor base of t... |
| 01.05.2024 | Xtalks Announces its Life Science Webinar Calendar for May 2024 | https://www.xtalks.com Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, food, healthcare, laboratory technology, m... |
| 15.04.2024 | Fully Automated cGMP Cell Therapy Manufacturing on Cellares' Cell Shuttle Platform, Upcoming Webinar Hosted by Xtalks | www.cellares.com In this free webinar, gain insights into a novel approach that can be useful for large-scale cell therapy manufacturing. Attendees will learn about Cellares' global network of Current Good Manufacturing Practice (cGMP) Inte... |
Show more